Trial Profile
A Phase 1/2 Study of Aflibercept Administered in Combination With Pemetrexed and Cisplatin in Patients With Advanced Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 15 Dec 2020
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Cisplatin; Pemetrexed
- Indications Carcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- 28 Nov 2013 Status changed from completed to discontinued according to results published in the British Journal of Cancer.
- 10 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2011 Planned end date changed from 1 Aug 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.